Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5fadc18369dac6778fe6217aed49ada7 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-60 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-4826 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-4833 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-4846 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-4853 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y304-21006 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-435 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-6432 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P39-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02 |
classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-64 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-48 |
filingDate |
2008-09-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate |
2020-11-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ed408b632dc69d42cfd0445ffc4519e0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_abf6c738d0ea1b72717dbace5593c3be http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e652cb1cf998325aa0d2c5b27a137378 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_efb2211f16469f38c373c4d4aca72098 |
publicationDate |
2020-11-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
ES-2796623-T3 |
titleOfInvention |
Antidotes to Factor Xa Inhibitors and Procedures for Using Them |
abstract |
A pharmaceutical composition comprising a carrier and a polypeptide for use in therapy wherein the polypeptide comprises an amino acid sequence that has at least 80% homology with SEQ ID NO. 12, where the polypeptide: (i) has reduced catalytic activity; (ii) is capable of binding to a factor Xa inhibitor; and (iii) cannot assemble into the prothrombinase complex. |
priorityDate |
2007-09-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |